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Abstract
Explaining precisely how Alzheimer’s disease (AD)—the world’s most common form of
dementia—materializes in the human brain has proven to be one of the most elusive ends
in modern medicine. Progressive memory loss, neurodegeneration, and the presence of
abnormal protein aggregates of amyloid-beta (Aβ) and neurofibrillary tangles (NFT)
characterize this disease. Genome sequencing provides researchers with the ability to
better identify disease-related changes in gene expression, some of which may play a role
in the initiation and progression toward the AD-like state. Intimate interactions between
tissues have been observed in many diseases, particularly between the brain and blood.
This analysis seeks to employ RNA sequencing techniques in the brain in order to
identify potential drivers, molecular passengers, and significant contributors to AD, while
overlaying this data with that of the blood to identify candidate genes to be used as
disease biomarkers.
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Gene Expression Profiling in an Alzheimer’s Disease Mouse Model
Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common form of dementia in the world and
is characterized by progressive memory loss, neurodegeneration, and the presence of
protein aggregates such as amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFT)
(1, 2). The two major risk factors for AD are age and sex (3, 4). In fact, females are
nearly twice as likely to develop AD than males (5). Diagnosing the disease has proven to
be difficult because tests are primarily based on cognitive performance, not the detection
of molecular indicators. The expression profile of an AD brain is substantially different
from that of a normal brain, which suggests that the disease takes root from an abnormal
regulation of genes (6, 7). Investigation of these changes in expression is a necessary next
step in understanding the pathophysiology of AD.
Gene Expression Profiling
Gene expression profiling (GEP) allows for the efficient analysis of dysregulated
genes in a given tissue. RNA-sequencing (RNA-Seq) is one of the most popular
contemporary techniques used in GEP studies (8). When applying this technique to
human diseases, researchers can isolate key genes that may influence the progression
toward a disease-like state. This is because the AD brain exhibits significantly altered
gene expression patterns when compared to a normal aged-matched brain (6, 7).
Similarly, other tissues, including blood, also exhibit these changes in expression (9-12).
For example, one GEP study identified 133 genes with irregular expression levels in AD
blood compared to controls (9).
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Research suggests that gene expression in one tissue can directly affect the
condition of neighboring tissues (13, 14). In fact, this principle serves as the basis for the
neurovascular hypothesis of AD, which proposes that AD pathogenesis begins with the
breakdown of the blood-brain barrier. According to this hypothesis, dysregulation of
various Aβ transport genes contribute to insufficient clearance of Aβ in the brain,
resulting in elevated levels and subsequent formation of plaques (13). Research indicates
that the blood-brain barrier plays a complex role in AD, likely participating in both
upstream causes and downstream consequences of Aβ accumulation in the brain (14). In
other words, the loss of function associated with a weakened blood-brain barrier results in
the loss of cellular homeostasis. Despite this, individual cells within a tissue will strive to
reestablish proper homeodynamic range, likely increasing or decreasing specific neuronal
RNA transcripts. A host of genes, including those that code for micro RNA (miRNA),
have been identified as dysregulated in either the AD brain or blood, some of which are
significant in both, like that of miR-29b (15-17). That said, these changes in the blood
might reflect changes in the AD-brain, opening the door for a potential diagnostic tool for
AD from simple, non-invasive blood tests.
Currently, there is no blood-based diagnostic tool for AD. However, the
association between the breakdown of the blood-brain barrier and AD grants the
possibility of developing such a tool. To this end, the analysis presented here attempts to
identify AD-specific changes in the brain and blood to identify candidate genes for use in
a blood-based AD diagnostic tool. The development of such a tool will enhance the
diagnosis of AD in early to late stages and holds the potential to identify those who have
an increased genetic risk for developing AD but have yet to show symptoms.
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Brief Overview of Micro RNA
Micro RNA (miRNA) are small non-coding RNA that are approximately 22
nucleotides long. Although small, miRNA play crucial roles in post-transcriptional
regulation of various protein-coding genes. In fact, miRNA are estimated to be involved
in the regulation of at least one-third of the mammalian genome (18). Since their
discovery in 1993, miRNA have been shown to be key regulatory elements in various
fundamental biological processes, including embryogenesis, cell differentiation, and
apoptosis. Given their vital role in biological systems, it is no surprise that the
dysregulation of miRNA have also been tied to various human pathologies, particularly
cancers.
The mechanism by which miRNA operates requires the concerted efforts of
several proteins (Appendix A). The gene encoding a specific miRNA is expressed to
produce a pri-miRNA molecule in the cell’s nucleus (19). In the nucleus, pri-miRNA is
cleaved via the Drosha-DGCR8 complex to produce pre-miRNA (20). Exportin 5 permits
the selective transport of pre-miRNA out of the nucleus and into the cytoplasm, where
further modification takes place (21). In the cytosol, Dicer protein cleaves the premiRNA to create a double-stranded miRNA that ultimately unwinds to produce mature
miRNA (22). Once unwound, the miRNA associates asymmetrically with the RNAinduced silencing complex (RISC) and directs RISC to complementary messenger RNA
(mRNA) (23). Most miRNA form mismatched duplexes with their targets, primarily
binding to the 3’ untranslated region (UTR) of the target mRNA (23). Consequently,
mismatched base pairing allows a single miRNA to have multiple targets. Once RISC has
been associated with the appropriate mRNA target, post-translational regulation occurs
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either by repression of translation or by direct mRNA cleavage, preventing the
production of the specific protein the mRNA encoded (24).
MiRNA pose an interesting problem to GEP studies. Due to their small size and
the absence of a poly(A)-tail, miRNA are difficult to detect in RNA-Seq analyses unless
specifically targeted. Therefore, most GEP studies fail to account for miRNA in their
analysis.
Challenges to Alzheimer’s Disease Research
One of the primary challenges of AD research is distinguishing which factors of
AD are driving the disease and which are merely passengers in AD pathology. Analysis
of specific genes changing expression in AD will yield a superior understanding of the
mechanisms involved in its development and may help distinguish which characteristics
of the disease are molecular drivers, important contributors, or passengers in AD
pathology. This investigation applies RNA-Seq techniques to help identify these
important players in AD pathology by determining the expression “profile” of AD in the
blood and brain. Furthermore, this project overlays these profiles with one another to
determine candidate genes to be included in a diagnostic tool for AD.
Another challenge to AD-directed research is the presence of inconsistent results
between labs. This issue arises primarily from three experimental caveats: (i) the type of
experimental model used in investigation, (ii) tissue samples, and (iii) sex of sample
population. Although animal models do provide experimental flexibility, human cohort
studies are considered the “gold standard” in AD research. However, for the purpose of
GEP studies, postmortem tissues would provide additional experimental freedom and
practicality. In light of this, the investigation presented here employs an AD transgenic
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mouse model with two human genes (APP and PSEN1) in the attempt to obtain a robust
experimental model in the absence of human tissues.
Variability between labs as a result of tissue selection is common due to the
variety of samples investigators may use, each having its own tissue-specific expression
profile. Hippocampus, cortex, blood, and skin are commonly used, with skin in the
minority (7, 9, 25). For the purposes of this analysis, differential expression in the
hippocampus and blood were analyzed.
Inconsistencies in experimental results may arise from sex-specific changes in AD
due to the involvement of sex hormones like testosterone and estrogen. In fact, estrogen
is suspected to provide neuroprotective effects against the development and severity of
AD (26, 27). This analysis utilized male AD mice and compared their expression profiles
to that of control males and females. Male controls were used to minimize estrogendependent changes in gene expression while females were used to help identify
dysregulated transcripts that are sex-independent via cross analysis. Despite this, sexual
dimorphism is likely to still play a role in this investigation.
Characteristics of Alzheimer’s Disease
Hallmarks of Alzheimer’s Disease
The classic hallmarks of AD include progressive memory loss,
neurodegeneration, and the presence of abnormal protein aggregates including Aβ
plaques and NFT (1, 2). Sleep disturbances have also been reported in approximately
45% of cases, generally presenting as an irregularity in circadian rhythm such as
excessive daytime sleepiness and insomnia at night (28, 29). Phenotypically, the size of
an AD brain is significantly smaller than that of a healthy aged-matched brain,
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predominantly attributed to atrophy of affected regions (30). On a cellular level, Aβ and
NFT are suspected to be responsible for inducing neuronal apoptosis (programmed cell
death) (31). Furthermore, the histological presentation of Aβ plaques and NFT are
positively correlated with severity of the disease (31-33).
The cellular basis of AD is suspected to occur many years before a patient ever
experiences symptoms. As a result, most patients are diagnosed within the later stages of
the disease, making management difficult. Symptoms in the earliest stages of the disease
include short-term memory loss and difficulties in concentration (34). Moderate stages
are characterized by mood disorders, general confusion, long-term memory loss, and
changes in personality (34). As the disease progresses into its later stages, patients begin
to experience hallucinations, difficulties in motor function, and eventual loss of the
brain’s ability to control vital regulatory processes such as heart rate and breathing,
resulting in death (34, 35).
Amyloid-Beta and Neurofibrillary Tangles
Aβ has been reported to play many biological roles in the normal brain, including
protection against oxidative stress, enzyme phosphorylation, inflammation, neuronal
differentiation, and regulation of cholesterol transport (36-39). In a diseased brain,
however, hydrophobic fragments of Aβ are deposited in the extracellular matrix of
neurons (40, 41). These fragments spontaneously associate with one another to form
insoluble protein aggregates that ultimately result in neuronal death and subsequent
neurodegeneration (42). Most researchers believe that the deposition of Aβ in the brain
initiates the pathophysiological cascade of AD (33). However, other hypotheses have
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been proposed overtime, with a considerable body of evidence, warranting further
investigation.
One such hypothesis holds to the proposition that neurofibrillary tangles (NFTs),
not Aβ, initiate the AD cascade (43). NFTs are primarily composed of tau protein
polymers, which are responsible for the stabilization of microtubules in neurons.
Microtubules are critical building blocks of the cytoskeleton. Aberrant phosphorylation
of tau, such as that observed in AD, leads to the breakdown of the cytoskeleton. With
respect to AD, breaking down a neuron’s cytoskeleton subsequently results in the
collapse of the intracellular transport system (44). As a result, these neurons ultimately
die due to an inability to acquire and distribute appropriate macromolecules necessary for
cellular functions.
Gene Expression in Alzheimer’s Disease
Transcription and Gene Expression
The genes of a cell contain all the necessary information for life in the form of
DNA. Through a process known as transcription, DNA is converted to messenger RNA
(mRNA), which is eventually modified and transformed until being used to produce a
functional protein by an additional process called translation (Appendix B). These mRNA
molecules are known as “coding” RNA because they effectively code for proteins to be
used by the cell. Gene expression refers to the relative activity of a particular gene, which
is generally measured by the presence of the gene’s mRNA product. This allows for an
efficient and effective means to measure the expression level of a particular gene,
including other types of RNA that do not code for proteins but may play a key role in the
development of the disease.
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Gene expression profiling (GEP) requires examination of the entirety of expressed
genes in a given set of tissues to develop a “profile” of the cellular activity in those cells
(45). This includes a comparison to other tissue profiles to develop a coherent
understanding of cellular functions and the role of contextual cellular environments
influencing the activity of the tissue(s) under investigation. To accomplish this,
investigators commonly use either microarrays or next generation sequencing (NGS)
techniques to get a glimpse of the totality of cellular activities in a cell from the
perspective of the transcriptome (45, 46).
Traditionally, the cellular transcriptome is defined as the sum of all active mRNA
molecules within a cell or group of cells. However, this term is commonly used in a
broader sense to include all types of RNA, including non-coding micro RNA (miRNA),
ribosomal RNA (rRNA), and transfer RNA (tRNA) among others. Thus, disease-focused
studies that employ these techniques are intended to assist investigators in identifying
areas of the transcriptome that display abnormal patterns and examine certain genes
either responsible or associated with the disease.
Next Generation Sequencing (NGS)
NGS allows for the rapid sequencing of the transcriptome to determine
differential expression profiles in a fast and efficient manner at a relatively low cost (47).
Furthermore, NGS permits the identification of novel RNA isoforms and splicing sites
largely because the technique does not rely heavily on isoform-specific probes like
traditional methods (48). NGS is synonymous with RNA-Seq because this technique
directly sequences the RNA in a given group of cells, providing researchers with the
ability to determine which genes are active versus inactive and to what degree.
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Regulation in Alzheimer’s Disease
Gene activity and subsequent expression can be modulated by several factors. In
particular, epigenetic factors affect the expression profile of a given tissue by modifying
nuclear DNA in such a way that gene expression is affected without changing the genetic
code. A considerable amount of research has identified many genes in AD to be
epigenetically modified by chemical markers such as cytosine methylation. Whether or
not a particular gene is expressed within a cell or group of cells is determined by these
chemical markers. This phenomenon is heritable and has been shown to be influenced by
environmental stressors (49). That said, epigenetic changes may be the driving force
behind many of the observed AD-related changes in gene expression. Although
establishing the epigenetic basis of AD is not within the scope of this analysis, many of
the observed changes in gene expression are likely to have some basis in the modification
of epigenetic markers.
AD does not follow a traditional pattern of inheritance. Several studies have
identified epigenetic changes in the DNA of AD patients (50-53). Additionally, multiple
studies have identified epigenetic changes in genes that code for miRNA responsible for
critical regulatory processes in the cell (54-56). Furthermore, several miRNA have been
previously identified as playing a key role in the progression of AD (57). This connection
highlights the importance of epigenetic changes in the development of AD and warrants
further investigation into the potential causative role of epigenetically modified miRNA
in AD pathophysiology.
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Experimental Design and Rationale
5XFAD Mouse Model
Mice are a common scientific model for understanding the complexities of human
pathogenesis. Because they share similarities in much of their genome, mice exhibit
many of the same diseases as humans (58). Using a mouse model allows for greater
flexibility of study and thus allows investigators to obtain a greater analysis of a
particular disease that otherwise would have been unethical in humans. Transgenic mouse
models are frequently used because they provide researchers with the ability to
selectively modify the organism’s DNA to produce a particular disease or disease-like
state, often by inserting human DNA in the mouse genome.
This investigation utilized the 5XFAD transgenic mouse strain. This strain
contains three human mutations in the amyloid-beta precursor protein (APP), including
the Swedish mutation (K670N/M671L), Florida mutation (I716V), and the London
mutation (V717I). Furthermore, the 5XFAD mouse model contains two human mutations
in the gene encoding presenillin 1 (PSEN1), including M146L and L286V designed to
overexpress mutant PSEN1 in neuronal tissue. Collectively, these five mutations are
associated with familial Alzheimer’s disease (FAD) in humans and work synergistically
in the accumulation of Aβ plaques. The APP and PSEN1 genes are both regulated via the
mouse Thy1 promoter, designed to aggressively overexpress these genes in the brain. As
a result, the 5XFAD strain elicits the characteristic features of human AD pathology in
mouse nervous tissue, including neurodegeneration, Aβ plaques, and NFT. The 5XFAD
mouse strain provides a robust AD transgenic mouse model that results in the
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development of Aβ plaques at 2 months, cognitive impairment at 4 months, and neuronal
apoptosis at 9 months of age (59).
RNA-Sequencing
This analysis utilized NGS to obtain a comprehensive, genome-wide analysis of
gene expression patterns in the 5XFAD mouse strain using two different tissues:
hippocampus and blood. Progression of AD is well documented in the hippocampus and
its effects on the tissue are well-known. Furthermore, there is a strong correlation
between severity of disease and presence of characteristic AD features in this region of
the brain, specifically Aβ plaques, NFT, and cognitive decline (60, 61). Blood tissue was
also collected to investigate the role of the blood-brain barrier in AD pathology and to
use this data to determine candidate genes for an AD diagnostic tool.
Several studies highlight a parallel correlation between gene expression changes
in the brain and blood (11, 17, 62, 63). Furthermore, a considerable amount of evidence
suggests an intimate interaction between the AD brain and peripheral leukocytes (9, 10,
64-66). Transcription factors that are involved in cardiovascular disease have also been
identified as being dysregulated in the AD brain (67, 68). These studies suggest a
possible involvement of tissue-specific crosstalk between the blood and brain that may be
utilized to identify genetic risk factors or disease-contributing genes in the brain from
simple, non-invasive blood tests.
The following was done in collaboration with Amanda Házy: RNA was isolated
and purified from the brain and blood of nine mice (3 5XFAD AD males, 3 normal
males, and 3 normal females) for comparison. Purified RNA was then reverse transcribed
into cDNA and sequenced using an Illumina MiSeq gene sequencer. Expression data
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were then normalized to control mice to determine significantly dysregulated genes in
both tissues. Ten significant genes were selected to be analyzed in the brain based on pvalue (≤ 0.05) and tested using RT-qPCR. Gene-by-gene confirmations were normalized
using endogenous controls (Tubb3 and Gapdh).
Selection of Endogenous Control Genes
Suitable endogenous control genes were selected based upon the following
criteria: (i) high expression in control and AD samples to ensure detection, (ii) minimal
variation between those samples to increase experimental consistency as (relatively)
constitutively expressed genes, (iii) gene primers exhibited melt curves with single peaks
to minimize qPCR side reactions, and (iv) genes displayed primer efficiencies
consistently near 1 to maximize uniform amplification cycles. Tubb3 (beta-tubulin 3) was
shown to be a sufficient control for the purposes of this analysis, although the relative
abundance in the blood of normal males was not ideal. Gapdh (glyceraldehyde-3phosphate dehydrogenase) was also shown to be a suitable control gene for AD male v.
normal female (brain and blood), however its adventitious expression in the brain of
normal males made it insufficient as an endogenous control gene in male hippocampal
tissue.
Micro RNA Analysis
Several studies have identified a correlation between dysregulated miRNA and
the AD-like state, many of which display epigenetic modifications (56, 69, 70). For the
purposes of this study, miRNA with demonstrated epigenetic modifications were
analyzed using a miScript PCR primer assay (Qiagen) to determine relative expression
patterns of miRNA compared to that of endogenous controls, Tubb3 and Gapdh. MiR-17,
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26b, 92, and 702 have been previously identified by our group as being epigenetically
modified in terms of methylation status (data not shown).
Experimental Methods
Mouse Euthanasia
Three male 5XFAD mice were used for this analysis and data from these mice
were normalized using three normal males and three normal females. Mice were
euthanized with carbon dioxide and sacrificed by decapitation in accordance to the
Institutional Animal Care and Use Committee (IACUC) accepted protocol. Once
euthanized, mouse tissues were obtained for RNA isolation.
RNA Isolation
RNA was isolated from the hippocampus and blood of each mouse. To
accomplish this, the hippocampus was dissected and homogenized in 1 mL Trizol per 50100 mg tissue (Invitrogen). Blood was obtained via cardiac puncture and placed in EDTA
tubes for subsequent centrifugation (10 minutes) to isolate RNA-rich leukocytes.
Subsequently, 100 μL of cells per sample were then homogenized in 1 mL Trizol. After
homogenization in Trizol, tissues were incubated at room temperature for 5 minutes
followed by the addition of 0.2 mL chloroform per 1 mL Trizol. Samples were then
subjected to centrifugation (12,000 x g for 15 minutes) before removal of the RNA-rich
aqueous phase. RNA precipitation was performed by adding 0.5 mL of isopropanol per 1
mL of Trizol for 10 minutes at 4 ˚C. RNA was pelleted by centrifugation at 12,000 x g
for 10 minutes. The precipitate was washed with 75% ethanol and centrifuged at 12,000 x
g for 5 minutes. Samples were then allowed to dry and resuspended in 50 μL DEPCtreated water.
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cDNA Preparation
A MiScript II RT kit (Qiagen) was used for cDNA preparation. Conversion to
cDNA and subsequent purification was accomplished by following manufacturer’s Hiflex
protocol to obtain a final cDNA concentration of 2.5 ng/μL.
For comparison to the MiScript protocol, an iScript cDNA Synthesis kit (BioRad)
was also used to test the reliability and sensitivity of each kit. A final cDNA
concentration of 2.5 ng/μL was synthesized from RNA according to the manufacturer’s
protocol.
RNA Sequencing and Analysis
The following RNA Sequencing methods were done in collaboration with
Amanda Házy: Each cDNA sample was prepared and sequenced using an Illumina
MiSeq sequencer, according to manufacturer’s protocol. Sequencing quality was assessed
using the Galaxy platform. FastQ files were imported into the Galaxy server for
differential expression analysis and the FastQ Groomer tool was used to prepare data for
downstream analysis using the Tuxedo suite. FastQ files were aligned to the mm9
reference genome using TopHat and BowTie. Two separate FastQ files resulted and were
combined through the TopHat/BowTie software.
Cufflinks software was used to assemble transcripts and determine FPKM value
(fragments per kilobase of transcripts per million mapped reads). Furthermore, a
maximum intron length of 300,000, minimum isoform fraction of 0.1, and a pre-mRNA
fraction of 0.15 was selected using the Cufflinks software. Additionally, various
corrective analyses were used to improve statistical significance (quartile normalization,
bias correction, multi-read correction, and effective length correction). The UCSC
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RefFlat table for the mm9 mouse genome was used as a reference annotation for
Cufflinks, which allowed for differential transcript expression, splicing, and promoter
use. Cuffmerge was used to combine accepted hits from TopHat to align AD samples to
background. Cuffdiff and Cufflink files were then converted to csv format to allow
compatibility of sequencing results with Microsoft Excel. Using these files,
CummeRbund software was employed to visualize data and gene ontology was assessed
using GeneCodis (71-73).
RT-qPCR Confirmations: miRNA and mRNA
RNA isolated from the hippocampus of AD males and normal females was
converted to cDNA and analyzed using a MiScript RT II kit (Qiagen), according to
manufacturer’s protocol for HiFlex (mRNA and miRNA) and HiSpec (miRNA only)
detection of transcripts by qPCR. Data were then analyzed, normalized, and converted to
log2 fold change to visualize the direction and significance of dysregulation.
Results
RNA-Sequencing Analysis
AD male versus normal female. RNA-Seq analysis identified 2250 genes to
have demonstrated changes in gene expression in the hippocampus of AD males when
compared to that of normal females (Figure 1). Of these genes, 230 were significantly
dysregulated in the AD hippocampus (Figure 1A). Statistical significance was determined
using a p-value ≤ 0.05. In the AD blood, 58 genes were identified to be dysregulated and
8 were shown to be significant in both the brain and blood of AD (Figure 1B).
AD male versus normal male. The second RNA-Seq ananlysis identified 729
genes displaying significant changes in gene expression in the male AD hippocampus
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when compared to that of normal males (Figure 2). These genes were determined to be
statistically significant as assessed by a p-value of ≤ 0.005. Similarly in the blood of AD,
151 genes were determined to exhibit expression changes compared to that of normal
blood. Of these genes, 75 were revealed to have been statistically significant expression
in both the brain and blood.

Figure 1. Differential expression in AD hippocampus and blood in AD male/female control. (A) AD
male hippocampus and blood were normalized to that of a normal female revealing 2250 dysregulated
genes, 230 of which were significantly dysregulated. P-value > 0.05 is illustrated in blue while those with a
p-value ≤ 0.05 are depicted in red. Twenty-four genes demonstrated significant expression changes in the
AD hippocampus (red) compared to that of control mice. (B) RNA-Seq data from AD male and normal
female are plotted on the x and y axis for each tissue under investigation (hippocampus and blood,
respectively). 8 genes were shown to be significantly dysregulated in both the brain and blood (red). Figure
courtesy of Amanda Házy.
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Figure 2. Differential expression in AD hippocampus and blood in AD male/male control. RNA-Seq
in AD male/male control revealed 729 genes that significantly (p-value ≤ 0.005) dysregulated in the brain
while only 151 were identified in the blood. The union of these genes revealed 75 that are significant in
both tissues.

Comparative RNA-Sequencing analysis in brain. Comparative analysis of
differential RNA-Seq data in the brain across sexes revealed 4 genes that displayed
significant changes in gene expression in AD males when compared to that of both
normal males and females (Figure 3). Statistical significance was assessed based on pvalue ≤ 0.0005. The genes Ctsz, Hexa, Tyrobp, and Laptm5 were all observed to be upregulated in both analyses. Gene ontology of these genes revealed immune cell regulation
and differentiation, proteolysis, and inflammation as major biological processes that are
affected in the AD brain (Table 1).
Comparative RNA-Sequencing analysis in brain and blood. Genes that were
found to be dysregulated in the AD male/control female analysis were compared to those
found in the AD male/control male analysis to determine sex-independent changes in AD
blood and brain. Significance was determined using a p-value ≤ 0.05. One gene, Hmgn1
(high mobility group nucleosomal binding domain 1), was observed to be significant in
all tissues, regardless of the sex used for normalization. Gene ontology of Hmgn1
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revealed an involvement in gene expression and cellular differentiation by association
with nucleosome binding (74).

Figure 3. Comparative RNA-sequencing analysis in hippocampus. Significant (p-value ≤ 0.0005) genes
in the hippocampus of the AD male/male control analysis were overlaid with those found to be significant
in the AD male/female control analysis. The union of these two lists revealed 4 genes (Ctsz, Hexa, Tyrobp,
and Laptm5) that were significantly dysregulated regardless of the sex by which the data were normalized.
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Symbol

Name

Tyrobp

Tyro protein tyrosine

Regulation
(Up/Down)
Up

AD
Connection
Yes (75-77)

kinase-binding protein
Hexosaminidase

Hexa

23

GO
Category
Immune cell
regulator

Up

Yes (78-80)

subunit alpha

Cell differentiation,
Lysosome
organization,
Myelination

Ctsz

Cathepsin z

Up

Yes (81)

Proteolysis

Laptm5

Lysosomal protein

Up

Yes (82, 83)

Inflammation

transmembrane 5
Table 1. Gene ontology and significance in differential brain expression. Gene ontology of the 4
intersecting genes from RNA-Seq analysis in the brain was retrieved using GeneCodis (71-73). Ontological
analysis revealed cellular regulation, differentiation, proteolysis, and inflammation as major biological
processes that are affected in AD. Regulation Up/Down represents the relative abundance in transcript
availability in AD compared to that of healthy controls.

Micro RNA Analysis
Of the genes previously identified by our group to be epigenetically modified,
miR-17 displayed significant dysregulation in the AD hippocampus when compared to
endogenous controls (Figure 4). An average log2 fold change of 2.16 (n=3) was observed
in miR-17, demonstrating significant up-regulation. In contrast, miR-26b, miR-702, and
miR-92 did not show significant changes with respect to gene expression despite their
reported changes in methylation status.
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3.5

Log2 Fold Change in AD/Control

3
2.5
2
1.5
1
0.5
0

n=1

n=2

n=3

Average

Figure 4. Significant up-regulation of miR-17. Gene expression levels of epigenetically modified miR-17
was identified using the miScript primer assay in triplicate (3 AD males vs 3 normal females) and
normalized using the endogenous controls Gapdh and Tubb3. On average, miR-17 was identified to exhibit
a fold change of 2.16 (1.54, n=1; 1.41, n=2; and 2.97, n=3).

Gene-by-Gene Confirmations via qPCR
The MiScript (Qiagen) and iScript (BioRad) cDNA synthesis kits were compared
side-by-side to investigate reliability and sensitivity of cDNA synthesis. Relative
abundance of RNA transcripts as high or low count transcripts may result from
unintentional differences in cDNA amplification efficiencies associated with each kit.
That said, the selected cDNA synthesis protocols were compared with negligible
differences between them (data not shown), strengthening the reliability of subsequent
confirmations.
Gene-by-gene confirmations were conducted via qPCR on 10 randomly selected
genes that showed up as significant in the RNA-Seq AD male/normal male analysis. Of
these genes, three were confirmed as being significantly changed in the AD hippocampus
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when compared to that of normal male controls: Ercc2, Grn, and Ppia (Figure 5). Log2
fold change for each was assessed to determine direction of dysregulation and was found
to be -0.81, 2.4, and -1.1 for Ercc2, Grn, and Ppia respectively.

Figure 5. Gene-by-gene confirmations via qPCR in AD hippocampus. Of the 10 genes chosen for this
analysis, 3 confirmed reproducibly (n=3) via qPCR (Ercc2, Grn, and Ppia). (A) Ercc2 (blue) demonstrated
a consistent down-regulation with an average log2 fold change of -0.81. (B) Grn (red), on the other hand,
was found to be up-regulated in AD, exhibiting an average log2 fold change of 2.4. (C) Ppia (green) also
confirmed to exhibit gene expression changes and was shown to be down-regulated in AD (log2 fold
change of -1.1). (D) qPCR analysis confirmed significant gene expression changes in Ercc2 (blue), Grn
(red) and Ppia (green).
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Discussion
Up-regulation of miR-17 and Apoptosis
This study has demonstrated miR-17 to be significantly up-regulated in the male
AD hippocampus. Given that miRNA regulation occurs at the post-transcriptional level, a
dysregulation of miRNA subsequently modulates the expression levels of its targets. That
said, an analysis of miR-17 targets revealed genes that are responsible for foundational
biological processes, including those that are involved with neuronal apoptosis and
cellular proliferation. Several studies have suggested that early activation of apoptotic
pathways in the brain contribute significantly to the pathophysiology of AD.
The anti-apoptotic protein Bcl-2 (B-cell lymphoma 2) is involved in regulating
apoptosis and has been shown to be a target of miR-17, inducing autophagy and
subsequent apoptosis (84, 85). RNA-Seq data also revealed Bcl-2 to be down-regulated in
the AD brain when compared to controls (data not shown). Furthermore, one study found
that overexpressing Bcl-2 in a transgenic AD mouse model not only increased active
memory in mice, but also reduced the levels of Aβ plaques and NFT in the brain (85).
Thus, the targeting of Bcl-2 by miR-17 may promote apoptosis in the AD brain and
ultimately result in neuronal atrophy.
BMPR2 (bone morphogenic protein receptor type 2) is involved in regulating
neuronal apoptosis and has been reported as a miR-17 target (86). Indeed, RNA-Seq
analysis revealed BMPR2 to be down-regulated in the AD brain (data not shown).
Furthermore, one study showed that inhibition of BMPR2 induces apoptosis in some
tissues (87). Thus, miR-17 may play an active role in AD by mediating the inhibition of
BMPR2, likely contributing to early activation of apoptotic pathways such as caspase-3.
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MiR-17 has also been reported to target E2F, a family of key regulatory
transcription factors (TF) that are responsible for providing a cell with the means to
advance beyond the G1/S-phase checkpoint of the cell cycle (Appendix C). Several
studies have also identified an E2F-dependent apoptotic pathway that recruits many of
the same pro-proliferative genes activated in cell cycle progression (88, 89). E2F
ultimately induces the transcription of pro-apoptotic genes, initiating the first step of
catastrophic neuronal death in response to chemical stimuli (88). To complicate matters
further, some studies have reported that miR-17, in fact, promotes intracellular
proliferation of the E2F family, despite being one of its targets (90). A model proposed
by Cloonan and colleagues attempts to reconcile these seemingly contradictory results by
demonstrating that the miR-17 family can behave differently depending on the cellular
context. In other words, the activity of the miR-17 family is driven by the relative affinity
and concentrations of its targets within the cell (91). This is obtained by virtue of the fact
that miR-17 also targets several anti-proliferative transcripts with a greater affinity than
that of E2F, subsequently increasing its intracellular levels (90).
Furthermore, the E2F-dependent apoptotic pathway is driven by trophic factor
deprivation (cellular starvation), which is known to be associated with the collapse of the
cytoskeleton in response to the formation of NFT (44, 89). Taken together, these
observations suggest miR-17 may play a role in the E2F-dependent apoptotic pathway by
inhibiting anti-proliferative molecules that may interfere with responses to a proapoptotic stimulus (Appendix D). Although little is known about the association of the
E2F-dependent pathway in AD, much less the role of miR-17 in this pathway, the data
presented here highlights the potential involvement of this pathway in AD pathogenesis.
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Previous work by our lab has demonstrated that the gene encoding miR-17 is
hypomethylated in the AD hippocampus, affecting the relative abundance of this miRNA
in the tissue. This analysis has confirmed the significant up-regulation of miR-17 via
qPCR in the AD hippocampus. In light of the information mentioned above, epigenetic
changes in gene expression appear to play a significant role in the pathophysiological
progression of AD.
Down-regulation of Ercc2
The gene Ercc2 (XPD; excision repair cross-complementation group 2) is
responsible for transcription-coupled nucleotide excision repair, which allows a cell to
“proof read” and edit misplaced nucleotides in its DNA (mutations) before passing this
information on to its progeny (92, 93). Furthermore, failure for Ercc2 to respond to
mutations in the DNA appropriately results in an increased frequency of apoptosis (93).
The data presented here reveal that Ercc2 is slightly down-regulated in our model (log2
fold change of -0.81). Thus, it is likely that the differences in gene expression of Ercc2
may contribute to the cell’s reduced ability to prevent neuronal apoptosis, further
contributing to the development of AD in our model.
Up-regulation of Grn
Grn (granulin) is a growth factor that is involved in the positive regulation of
neuron projections such as axons and dendrites. Current research suggests that mutations
in Grn translate to an increased risk for development of various forms of dementia,
including AD (94-97). However, Grn likely plays a role as a disease-modifying gene as
opposed to a causative biochemical role in AD pathology, especially with respect to
sporadic development (98). Furthermore, one study showed that variations in the Grn
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gene are not even major contributors to late on-set AD (99). That said, the datum
presented here is consistent with other mouse models in that it indicates that Grn is
significantly up-regulated (log2 fold change of 2.4) in the AD brain (97). Increased Grn
gene expression is suspected to result from a corrective cellular response to AD
pathology, as other labs have suggested (98).
Down-regulation of Ppia
Ppia (CypA; peptidylprolyl isomerase A) assumes many biological roles in the
brain, most significantly neuronal differentiation and regulation of apoptosis (100, 101).
The data presented here reveal that Ppia is down-regulated in this model, suggesting a
disruption of these processes in the brain. Specifically, Ppia has been identified as a
necessary component of retnoic acid (RA) neuronal differentiation (101). Thus, these
data suggest that the ability of the AD brain to differentiate has been diluted due to a
decreased availability of this protein in the cytosol, leading to reduced plasticity of these
cells that may contribute to AD. Additionally, Ppia has been shown to initiate the
production of the antiapoptotic protein, Bcl-2 (102). This suggest that the AD brain’s
ability to resist apoptosis is further reduced because of the down-regulated nature of Ppia.
The collective effects of miR-17 and Ppia on Bcl-2 demonstrate the importance of Bcl-2
protein in the pathophysiology of AD. Furthermore, the weakened ability of the AD brain
to undergo differentiation results in insufficient neuronal specificity.
Differential RNA-Sequencing Analysis
Individual RNA-Seq data files (AD male vs. normal female, AD male vs. normal
male) resulted in major differences by which genes were considered “significant.” One
explanation is that males and females are highly dimorphic with respect to the regulation
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of their genomes. Specifically, differential expression of steroid hormones, particularly
estrogen and testosterone, plays a significant role in gene expression and thus influence
GEP studies (103-106). The primary goal of the differential RNA-Seq analysis was to
determine candidate genes to be used in the development of a diagnostic tool for AD.
Thus, any potential biological markers for AD that are greatly affected by the relative
expression of estrogen and testosterone are insufficient for the purpose of a non-sexspecific diagnostic tool.
Several genes were observed to be dysregulated in the brain and blood of AD
mice, indicating that a breakdown of the blood-brain barrier may preclude the
development of the familial AD-like state. Hmgn1 was the only gene observed to be
dysregulated in both tissues, regardless of the sex used to normalize the data.
Furthermore, this analysis is the first to identify Hmgn1 as being dysregulated in the
brain and blood of AD. Although the involvement of Hmgn1 in AD is poorly defined, its
candidacy as a biological marker is solely contingent on the nature of its dysregulation
(Figure 6). Thus, Hmgn1 reveals itself to be a suitable candidate as a predictive
biomarker for AD.
The differential analysis of the AD brain revealed four significantly (p-value ≤
0.0005) dysregulated genes, all of which have been previously associated with AD to
some extent (Table 1). These genes are involved in several processes, notably
inflammation, differentiation, and immunological responses. Most importantly, these
genes are not sex-specific. Thus, their dysregulation is not ultimately dependent on
hormonal regulation. That said, this analysis adds to the growing body of evidence
suggesting the importance of these genes in AD pathophysiology.
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Figure 6. AD diagnostic indicator from GEP studies. Disease-specific changes in the blood and brain
could be utilized in a diagnostic test for AD. Significantly dysregulated genes in each tissue can be assessed
using a simple, non-invasive blood test that parallels changes in the brain leading to an effective and costefficient diagnostic tool.

Conclusion
AD is one of the greatest medical and social challenges of this generation.
Although the disease had been characterized for over 100 years, AD-directed therapies
today provide virtually no clinical improvement to those who suffer from this disease.
This issue stems from the fact that very little is known about the pathophysiology of AD.
A comprehensive understanding of AD necessarily entails two primary discoveries: (i)
elucidation of genetic drivers, important contributors, and mere passengers of the disease,
and (ii) effective, systematic diagnostic means.
This investigation adds to the growing body of evidence that suggest Tyrobp,
Hexa, Ctsz, and Laptm5 are central to the progression of AD while also highlighting
additional genes that seem to play vital roles in the progression toward the disease state.
Mir-17 plays a critical prima facie role as a genetic driver of AD pathophysiology,
particularly because of its responsibility in targeting regulatory genes involved in
neuronal apoptosis and proliferation in addition to its demonstrated epigenetic status.
Additionally, this analysis identified four probable important contributors to AD
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pathology: Bcl-2, BMPR2, E2F, and Ercc2. Furthermore Grn was highlighted in this
analysis, displaying significant dysregulation likely due to its role as a passenger of AD,
not a contributor.
Current diagnostic means for AD are not only ineffective but are also costly and
invasive. Improved understanding of the blood-brain barrier in AD yields the potential
for the development of a multi-gene diagnostic “cocktail” that serves as a predictive
biological marker for AD. Hmgn1 was shown in this analysis to be significantly
dysregulated in both the blood and brain of AD, regardless of sex. Thus, Hmgn1 is a
strong candidate gene for incorporation into a diagnostic tool of this nature.
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Running head: GENE EXPRESSION PROFILING IN ALZHEIMERS DISEASE
Appendix A

The miRNA mechanism. A gene that encodes an miRNA is transcribed to produce a pri-miRNA
molecule, which is then converted into a pre-miRNA via the Drosha protein (not shown). Pre-miRNA is
then exported into the cytoplasm where Dicer cleaves the pre-miRNA into a double-stranded RNA
fragment (miRNA duplex). The fragment then unwindes, becoming a mature miRNA. The miRNA
associates with RISC and its target mRNA to create the RISC complex, either cleaving the target mRNA
directly or repressing its translation.
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Appendix B

DNA
Transcription

RNA
Translation

Protein
Central dogma of biology. Chemical information is stored in the form DNA (blue) in the nucleus of a cell.
This information is converted into RNA (red) by a process called transcription. RNA is then modified and
translated into protein (green), the chief actor of the cell. Next generation sequencing (NGS) often utilizes
the accessibility of RNA, typically mRNA, to infer either the relative abundance of a protein,
transcriptional activity of the gene, or both within a given cell.

GENE EXPRESSION PROFILING IN ALZHEIMERS DISEASE
Appendix C

The cell cycle. Active cells must progress through a series of definite stages before cellular proliferation
(i.e. division) may take place. These stages consist of interphase (blue) and mitosis (dark red). Interphase
can be further divided into three sub-phases: G1, S, and G2. As the cell cycles through these stages in
preparation of mitosis, two cellular “checkpoints” must be successfully passed (C1 and C2, light red). In
order to pass C1, free E2F must be present in order to initiate transcription in preparation for S-phase.
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Appendix D

Regulation of the apoptotic E2F-dependent pathway. Stimulus via trophic factor deprivation promotes
the activation of the apoptotic E2F-dependent pathway, which responds by increasing the transcription of
pro-apoptotic genes. (A) Under normal conditions miR-17 targets E2F, regulating its activity by silencing
the transcript to keep it within a normal homeodynamic range. (B) Anti-apoptotic proteins are also
responsible for keeping E2F within homeodynamic range. However, miR-17 exhibits an increased affinity
(C) for the transcripts of these anti-apoptotic proteins. Thus, under the correct intracellular conditions, like
that in the activation of the apoptotic E2F pathway, miR-17 can have a proliferative effect on E2F activity
by virtue of the fact that it is “distracted.” This complex regulation pathway illustrates the importance of
maintaining each molecular component of a cell to ensure proper cellular functionality.
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From: Amanda Hazy <amanh15@vt.edu>
Sent: Sunday, May 8, 2016 8:15 PM
To: Dalton, Matthew R
Subject: Re: Graph permission
Matt,
You have my permission to use those graphs in your thesis. Enjoy the rest of your
semester!
Amanda
On Sat, May 7, 2016 at 5:29 PM, Dalton, Matthew R <mdalton15@liberty.edu> wrote:
Hi Amanda,
I hope this message finds you well. As a requirement of the Digital Commons, I am
requesting written permission from to include a couple of your graphs in my
honors thesis:
Fig 1. "Differential expression in AD hippocampus and blood in AD male/female
control."
Fig 6. "AD diagnostic indicator from GEP studies."
I have attached a copy of my thesis for your convenience.
All the best,
Matt Dalton
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